(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 October 2005 (27.10.2005)

PCT

(10) International Publication Number
WO 2005/100350 A1

(51) International Patent Classification: C07D 451/04, A61K 31/46, A61P 1/00

(21) International Application Number: PCT/US2005/011393

(22) International Filing Date: 6 April 2005 (06.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/560,076 7 April 2004 (07.04.2004) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/560,076 (CIP)
Filed on 7 April 2004 (07.04.2004)

(71) Applicant *(for all designated States except US)*: **THERAVANCE, INC.** [US/US]; 901 Gateway Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MARQUESS, Daniel** [GB/US]; 2037 Touraine Lane, Half Moon Bay, CA 94019 (US). **FATHEREE, Paul, R.** [US/US]; 921 Minnesota Street, San Francisco, CA 94107 (US). **TURNER, Derek, S.** [US/US]; 804 Fell Street, San Francisco, CA 94117 (US). **LONG, Daniel, D.** [GB/US]; 3855 21st Street #3, San Francisco, CA 94114 (US). **CHOI, Seok-Ki** [KR/US]; 525 Embarcadero Road, Palo Alto, CA 94301 (US). **GOLDBLUM, Adam, A.** [US/US]; 505 Molimo Drive, San Francisco, CA 94127 (US). **GENOV, Daniel** [BG/US]; 888 O'Farrell Street, Apt. W405, San Francisco, CA 94109 (US).

(74) Agents: **HAGENAH, Jeffrey, A.** et al.; Theravance, Inc., 901 Gateway Boulevard, South San Francisco, CA 94080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/100350 A1

(54) Title: QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT$_4$ RECEPTOR AGONISTS



(I)

salt or solvate or stereoisomer thereof.

(57) Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds of Formula (I). The invention also provides pharmaceutical compositions comprising such compounds, the use such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds. Wherein; R^1 is hydrogen, halo, hadroxy, C_{1-4} alkyl, or C_{1-4} alkoxy; R^2 is C_{3-4} alkyl, or C_{3-6}cycloakyl; R^3 is hydrogen or C_{1-3} alkyl: R^4 is —$S(O)_2$ R^6 or—C(O)R^7; R^5 is hydrogen, C_{1-3}alkyl, C_{2-3} alkyl subtituted with -OH or C_{1-3} alkoxy, or—CH_2—pyrydyl; R^6 is C_{1-3} alkyl; or R^5 and R^6 taken together from C_{3-4} alkylenyl; and R^7 is hydrogen, C_{1-3}alkyl, or pyrydyl; or pharmaceutically-acceptable